Ovid Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
OVID$2.85+10.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $27,041,517 | $44,867,846 |
| Marketable securities | 78,791,858 | 84,133,565 |
| Prepaid expenses and other current assets | 3,764,332 | 2,379,280 |
| Total current assets | 109,597,707 | 131,380,691 |
| Long-term equity investments | 17,625,620 | 5,622,547 |
| Restricted cash | 1,930,753 | 1,930,753 |
| Right-of-use asset, net | 13,894,376 | 14,922,669 |
| Property and equipment, net | 768,753 | 1,147,963 |
| Other assets | 209,574 | 261,191 |
| Total assets | $144,026,783 | $155,265,814 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,702,936 | $1,952,910 |
| Accrued expenses | 6,525,235 | 4,504,669 |
| Current portion, lease liability | 1,246,119 | 533,946 |
| Total current liabilities | 11,474,290 | 6,991,525 |
| Long-term liabilities: | ||
| Lease liability | 14,755,606 | 16,001,725 |
| Royalty monetization liability | 30,000,000 | — |
| Total liabilities | 56,229,896 | 22,993,250 |
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at December 31, 2023 and 2022 | 1 | 1 |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 70,691,992 and 70,466,885 shares issued and outstanding at December 31, 2023 and 2022, respectively | 70,692 | 70,467 |
| Additional paid-in-capital | 365,590,993 | 357,770,825 |
| Accumulated other comprehensive income (loss) | 702 | (42,187) |
| Accumulated deficit | (277,865,501) | (225,526,542) |
| Total stockholders' equity | 87,796,887 | 132,272,564 |
| Total liabilities and stockholders' equity | $144,026,783 | $155,265,814 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.